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Abstract
Background: Anxiety disorders are a highly prevalent and disabling class of psychiatric disorders. There is growing
evidence implicating the glutamate system in the pathophysiology and treatment of anxiety disorders, though the
molecular mechanism by which the glutamate system regulates anxiety-like behavior remains unclear.
Results: In this study, we provide evidence suggesting that tyrosine phosphorylation of the NMDA receptor, an
ionotropic glutamate receptor, contributes to anxiety-like behavior. The GluN2B subunit of the NMDA receptor is
tyrosine-phosphorylated: Tyr-1472 is the major phosphorylation site. Homozygous knock-in mice that express a
Tyr-1472-Phe mutant of GluN2B, which prevents phosphorylation of this site, show enhanced anxiety-like behavior in
the elevated plus-maze test. Expression of corticotropin-releasing factor (CRF), which is important for the regulation
of anxiety-like behavior, is increased in the amygdala of the knock-in mice. Furthermore, injection of CRF receptor
antagonist attenuated the enhanced anxiety-like behavior of the knock-in mice. We also show that elevated
plus-maze exposure simultaneously induced de-phosphorylation of Tyr-1472 and increased CRF expression.
Conclusions: These data suggest that Tyr-1472 phosphorylation on GluN2B is important for anxiety-like behavior
by negative regulation of CRF expression in the amygdala.
Background
Anxiety is commonly experienced and typically adaptive;
however, excessive and dysfunctional anxiety leads to
serious disorders. Anxiety disorders are the most preva-
lent class of psychiatric disorders in many countries [1].
Compounds that target of g-aminobutyric acid and the
serotonergic systems have received great attention
within the development of treatments for anxiety disor-
ders [2]. As some forms of anxiety are relatively resis-
tant to treatment with these compounds, which include
benzodiazepines and selective serotonin reuptake inhibi-
tors, it has become increasingly apparent that alternative
treatment strategies are needed. Recently, the glutama-
tergic system, the major mediator of excitatory synaptic
transmission in the mammalian brain, has been
the focus of pathophysiological studies of human
anxiety disorders [3]. In rodents, N-methyl-D-aspartate
(NMDA) receptor antagonists show anxiolytic effects in
several test scenarios including the elevated plus-maze
test [4,5]. While these reports point to the involvement
of NMDA receptor-mediated signaling in the regulation
of anxiety-like behaviors, molecular dissection of the
role of NMDA receptor-mediated signaling is difficult
because glutamate exerts its effects on various neural
functions in a highly complex manner [6].
The NMDA receptor is crucial for neural develop-
ment, synaptic plasticity, neuronal excitotoxicity, and
behavior [6-9]. The NMDA receptor is composed of the
GluN1 and GluN2 subunits: the GluN1 subunit is essen-
tial for the function of NMDAR channels, whereas the
GluN2 subunits (GluN2A, GluN2B, GluN2C, and
GluN2D) determine the characteristics of NMDAR
channels by forming different heteromeric configura-
tions with the GluN1 subunit [6]. The function of
NMDA receptor-mediated signaling is in part regulated
by Src tyrosine kinase-mediated phosphorylation of the
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GluN2 subunit [10,11]. Previous studies have found that
Tyr-1325 and Tyr-1472 are the principal tyrosine phos-
phorylation sites on the GluN2A and the GluN2B subu-
nits, respectively [12,13]. Genetically engineered mice
expressing the Y1325F mutation of GluN2A show anti-
depressant-like behavior, but their other neural func-
tions, such as hippocampal-dependent learning, are
normal [12]. Alternatively, mice expressing the Y1472F
mutation of GluN2B show a selective impairment in
amygdala-dependent fear-learning [13]. Considering the
versatile role of the NMDA receptor in various neural
functions [6], the phenotypes of these mutant mice are
milder than expected: thus these mice provide valuable
models in which to dissect the molecular basis of speci-
fic behaviors including anxiety-like behavior.
Corticotropin-releasing factor (CRF), which is highly
abundant in the amygdala as well as in the paraventricu-
lar nucleus of the hypothalamus, plays an important role
in regulating anxiety-like behavior [14]. Patients suffer-
ing from anxiety disorders often have increased CRF
levels in their cerebrospinal fluid [15,16]. In rodents,
intracerebro-ventricular delivery of CRF is anxiogenic
[17]. Likewise, transgenic mice overexpressing CRF exhi-
bit increased anxiety-like behavior [18]. Conversely,
CRF1 receptor knockout mice have reduced anxiety [17].
Injection of CRF antagonists or CRF1 receptor antisense
oligonucleotide into the amygdala reduces stress-
induced anxiety-like behavior [19,20]. These results
collectively show that CRF plays a key role in the regu-
lation of anxiety-like behavior particularly in the amyg-
dala. Therefore understanding the molecular mechanism
of the regulation of CRF expression in the amygdala is
important.
In the present study, using behavioral, pharmacologi-
cal, and biochemical approaches with knock-in mice in
which the Tyr-1472 of GluN2B is mutated to phenylala-
nine (GluN2B-YF), we have identified Tyr-1472 phos-
phorylation as a regulator of CRF mRNA expression
and anxiety-like behavior.
Results
Enhanced anxiety-like behavior of GluN2B-YF mice
Given that we previously found that GluN2B-YF mice
show a selective impairment in amygdala-dependent
learning [13], we evaluated amygdala-dependent anxiety-
like behavior in GluN2B-YF mice using the elevated
plus-maze (EPM) test, one of the most popular beha-
vioral tests for research on anxiety [21]. The measures
of anxiety are the percentage of time spent in the open
arms and the percentage of open arm entries. In the
test, GluN2B-YF mice spent less time in the open arms
than wild-type (WT) mice (time in open arms: WT,
41.5 ± 3.9%, n = 28; YF, 29.0 ± 3.5%, n = 31; F(1,57) =
5.516, p < 0.05, one-way ANOVA) (Figure 1A). We also
Figure 1 Enhanced anxiety-like behavior of GluN2B-YF mice in
the elevated plus-maze test. (A), (B) GluN2B-YF mice spent less
time exploring the open arms (WT, n = 28; YF, n = 31; F(1,57) =
5.516, p < 0.05, one-way ANOVA) (A) and made fewer entries into
the open arms (WT, n = 28; YF, n = 31; F(1,57) = 6.908, p < 0.05, one-
way ANOVA) (B) during the elevated plus-maze test. (C) Total
number of entries of GluN2B-YF mice into the open and closed
arms was not significantly different from that of WT mice (WT, n =
28; YF, n = 31; F(1,57) = 0.490, p > 0.4, one-way ANOVA). The asterisk
indicates significant genotype differences. n.s., not significant.
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found that GluN2B-YF mice showed a clear preference
for closed arms (percentage of entries into open arms:
WT, 50.8 ± 1.8%, n = 28; YF, 41.9 ± 2.7%, n = 31; F(1,57) =
6.908, p < 0.05, one-way ANOVA) (Figure 1B). There
was no significant difference in the number of total arm
entries between GluN2B-YF and WT mice (number of
total entries: WT, 44.6 ± 1.9, n = 28; YF, 42.6 ± 2.0, n =
31; F(1,57) = 0.490, p > 0.4, one-way ANOVA), suggesting
that the locomotor activity of the GluN2B-YF mice was
unchanged compared to that of WT mice (Figure 1C).
Together with the findings that spontaneous activity of
GluN2B-YF mice in the open field test was virtually nor-
mal compared to that of the WT mice (data not shown),
these results suggest that reduced open arm activity in
GluN2B-YF mice is due to increased anxiety rather than
motor impairment.
Increased CRF expression in the amygdala of
GluN2B-YF mice
Several neurochemical systems are implicated in anxi-
ety-related behavior in mice [3,22,23]. Among them, we
focused on CRF-mediated signaling because many stu-
dies have reported that CRF is involved in the fear-
potentiated EPM behavior [21]. Relative to wild-type
controls, we found, by real-time PCR, that GluN2B-YF
mice had markedly increased levels of CRF mRNA in
the amygdala, which regulates the behavioral systems
involved in the fear response (WT, 100.0 ± 7.3%, n = 5;
YF, 175.3 ± 41.5%, n = 5; p < 0.05, Student’s t-test)
(Figure 2A). Interestingly, slight changes in the levels of
CRF mRNA in other brain regions, including the hippo-
campus, cerebellum, and hypothalamus were not signifi-
cantly different (hippocampus: WT, 100.0 ± 10.3%, n =
5; YF, 115.7 ± 19.5%, n = 5; p > 0.2, Student’s t-test; cer-
ebellum: WT, 100.0 ± 25.2%, n = 5; YF, 145.7 ± 70.1%,
n = 5; p > 0.2, Student’s t-test; hypothalamus: WT,
100.0 ± 9.7%, n = 5; YF, 103.8 ± 16.1%, n = 5; p > 0.5,
Student’s t-test) (Figure 2B-D). To confirm the increased
CRF levels in the amygdala, we performed an ELISA and
found that CRF was indeed increased in the amygdalae
of GluN2B-YF mice (WT, 100.0 ± 4.4%, n = 10; YF,
120.4 ± 5.0%, n = 10; p < 0.01, Student’s t-test) (Figure
2E). As expected, there was no significant difference in
the CRF levels determined by ELISA in other brain
region such as hippocampus between GluN2B-YF and
WT mice (CRF levels in the hippocampus: WT, 100.0 ±
6.9, n = 10; YF, 105.3 ± 7.0, n = 10; p > 0.5, Student’s t-
test). In addition, given that CRF plays a key role in
hypothalamus-pituitary-adrenal (HPA) axis activation
[14], we examined the HPA axis-regulated plasma
ACTH levels by ELISA. We found that the plasma
ACTH level of GluN2B-YF mice was similar to that of
wild-type mice (WT, 419.5 ± 67 pg/ml (100.0 ± 16.0%),
n = 9; YF, 364.7 pg/ml (86.9 ± 13.2%), n = 13; p > 0.5,
Student’s t-test) (Figure 2F). This result suggests that
the function of HPA axis is normal in GluN2B-YF mice.
Thus, it appears that CRF expression is increased in the
amygdala but not in other brain regions of GluN2B-YF
mice.
Attenuation of enhanced anxiety-like behavior of GluN2B-
YF mice by CRF receptor antagonist
In the amygdala, CRF modulates anxiety-like behavior
by binding CRF1 receptor [16]. If the enhanced anxiety-
like behavior of GluN2B-YF mice were due to increased
CRF expression, blockade of the CRF1 receptor might
attenuate the enhanced anxiety-like behavior of
GluN2B-YF mice. To examine this possibility, we per-
formed the EPM test after injecting mice with the CRF1
receptor selective antagonist NBI 27914. There was a
significant interaction between genotype and NBI
27914-treatment for the time spent on open arms
(F(1,37) = 8.30, p = 0.0066, two-way ANOVA). Tukey’s
post-hoc test revealed that vehicle-injected GluN2B-YF
mice showed enhanced anxiety-like behavior relative to
vehicle-injected WT mice (time on open arms: WT,
32.7 ± 4.5%, n = 10; YF, 21.3 ± 2.6%, n = 12; F(1,37) =
7.12, p < 0.05, two-way ANOVA/Tukey’s post-hoc test)
(Figure 3). In contrast to the vehicle-injection, we found
that the enhanced anxiety-like behavior exhibited by
GluN2B-YF mice was attenuated by acute intraperito-
neal injection of NBI 27914 (time on open arms:
WT, 25.8 ± 2.6%, n = 8; YF, 36.5 ± 7.4%, n = 9; F(1,37) =
2.31, p > 0.1, two-way ANOVA/Tukey’s post-hoc test)
(Figure 3). These results argue that activated CRF1 recep-
tor-mediated signaling causes the enhanced anxiety-like
behavior of GluN2B-YF mice. In addition, in contrast to
the case seen in Figure 1, slight decrease in the number of
entries into open arms of vehicle-injected GluN2B-YF
mice was not significantly different (vehicle-injected WT,
48.5 ± 3.6%, n = 10; vehicle-injected YF, 40.1 ± 2.5%, n =
12; p = 0.08, two-way ANOVA/Tukey’s post-hoc test; NBI
27914-injected WT, 40.4 ± 5.0%, n = 8; NBI 27914-
injected YF, 42.8 ± 4.9%, n = 9; p = 0.68, two-way
ANOVA/Tukey’s post-hoc test), probably because of
injection stress [19].
De-phosphorylation of Tyr-1472 and increased CRF
expression in the amygdala of wild-type mice after the
EPM test
We next investigated whether the level of Tyr-1472 phos-
phorylation in the amygdala of wild-type mice was affected
by the EPM test. At 10 min after the test, the amygdala
was resected, and the total lysates and RNAs were
prepared. As shown in Figure 4A, the level of Tyr-1472
phosphorylation was significantly decreased in the amyg-
dala of wild-type mice exposed to the EPM test compared
with control wild-type mice (control: 100.0 ± 8.5%, n = 6;
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EPM test: 85.1 ± 5.3%, n = 4; p < 0.05, Student’s t-test).
Interestingly, the level of CRF mRNA in the amygdala was
increased by the EPM test (control: 100.0 ± 24.3%, n = 6;
EPM test: 168.7 ± 17.3%, n = 4; p < 0.05, Student’s t-test)
(Figure 4B). These data further support that Tyr-1472
phosphorylation is relevant to the anxiety-like behavior
and negative regulation of CRF expression in the
amygdala.
Induction of de-phosphorylation of Tyr-1472 and
increased CRF expression by NMDA receptor stimulation
We then examined whether NMDA receptor activity is
involved in the regulation of CRF expression in the
amygdala. Coronal sections including the amygdala were
stimulated with 100 μM NMDA for 7 min, followed by
a wash-out period of 15 min. Then, the amygdala was
rapidly dissected out and RNA was isolated to examine
Figure 2 Increased CRF levels in the amygdala but not in other brain regions in GluN2B-YF mice. (A)-(D) Real-time PCR analyses showed
that CRF mRNA levels were increased in the amygdala (WT, n = 5; YF, n = 5; p < 0.05, Student’s t-test) (A) but not in other brain regions,
including the hippocampus (WT, n = 5; YF, n = 5; p > 0.2, Student’s t-test) (B), cerebellum (WT, n = 5; YF, n = 5; p > 0.2, Student’s t-test) (C), and
hypothalamus (WT, n = 5; YF, n = 5; p > 0.5, Student’s t-test) (D), of GluN2B-YF mice compared to WT mice. (E) Increased expression of CRF in
the amygdala was confirmed by ELISA (WT, n = 10; YF, n = 10; p < 0.01, Student’s t-test). (F) The plasma ACTH level of GluN2B-YF mice was not
significantly different from that of WT mice (WT, n = 9; YF, n = 13; p > 0.5, Student’s t-test). The asterisk indicates significant genotype
differences. n.s., not significant.
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the level of CRF mRNA expression (Figure 4C). We
found that NMDA receptor stimulation increased CRF
mRNA expression in wild-type slices (control: 100.0 ±
10.5%, n = 6; NMDA stimulation: 160.1 ± 20.3%, n = 6;
p < 0.05, Student’s t-test). Interestingly, the same stimu-
lation also induced de-phosphorylation of GluN2B Tyr-
1472 (the level of Tyr-1472 phosphorylation: control,
100.0 ± 5.8%, n = 5; NMDA stimulation, 42.5 ± 3.1%,
n = 5; p < 0.05, Student’s t-test) (Figure 4D). In contrast
to wild-type slices, CRF mRNA expression levels in the
slices from GluN2B-YF mice were virtually unchanged
by the same NMDA stimulation (control: 153.3 ± 20.5%,
n = 6; NMDA stimulation: 143.1 ± 7.5%, n = 6; p > 0.2,
Student’s t-test) (Figure 4C). Thus, NMDA receptor sti-
mulation is a likely trigger for increased CRF mRNA
expression through de-phosphorylation of Tyr-1472 in
the amygdala.
Discussion
In this study, we showed that Tyr-1472 phosphorylation
of GluN2B is a negative regulator of CRF mRNA
expression in the amygdala. Behaviorally, deficient Tyr-
1472 phosphorylation leads to enhanced anxiety-like
behavior, which is consistent with enhanced CRF signal-
ing [14,17,18]. We further demonstrated that acute
intraperitoneal injection of NBI 27914, a selective CRF1
receptor antagonist, attenuated the anxiety-like behavior
of GluN2B-YF mice. Given the established role of CRF
in anxiety [14,16,17], it is likely that the enhanced anxi-
ety phenotype observed in GluN2B-YF mice is linked to
increased CRF expression in the amygdala.
Considering that Tyr-1472 phosphorylation is required
for the NMDA receptor-mediated signaling [13], the
present finding that GluN2B-YF mice exhibit increased
anxiety-like behavior is consistent with previous phar-
macological and genetic studies in rodents showing the
anxiolytic-like effects of NMDA receptor blockade
[24,25]. Strikingly, intra-amygdala injection of an
NMDA receptor antagonist, MK-801, prevents stress-
induced increases in anxiety-like behavior in the EPM
test [25], suggesting that NMDA receptors, especially in
the amygdala, play a key role in regulating anxiety-like
behavior. Interestingly, we found that the level of CRF
was markedly increased in the amygdala of GluN2B-YF
mice but not in other brain regions such as the hippo-
campus, cerebellum, and hypothalamus (Figure 2B-D).
Thus, the Tyr-1472 phosphorylation-dependent regula-
tion of NMDA receptors in the amygdala is likely to be
responsible for anxiety-like behavior. Tissue specific
conditional GluN2B-YF mice would be useful for ana-
lyzing the differential roles of Tyr-1472 phosphorylation.
CRF in the amygdala contributes to anxiety because
injection of CRF antagonists or CRF1 receptor antisense
oligonucleotides into the amygdala reduces anxiety-like
behavior in rats [19,20]. In amygdala-derived neuronal
cultures, NMDA receptor stimulation induces CRF
release [26], suggesting that a functional NMDA recep-
tor system regulates CRF signaling in the amygdala. In
this study, we found that the YF mutation in the
Tyr-1472 phosphorylation site leads to increased
CRF mRNA expression (Figure 2). Correlating with
this, NMDA receptor stimulation induced tyrosine de-
phosphorylation of Tyr-1472 and up-regulation of CRF
mRNA expression in amygdala slices (Figure 4). Thus,
Tyr-1472 phosphorylation links NMDA receptor activity
and CRF expression in the amygdala: however, the
mechanisms underlying enhanced CRF mRNA expres-
sion in GluN2B-YF mice remain to be determined. We
previously found that Tyr-1472 phosphorylation regu-
lates NMDA receptor-mediated CaMKII signaling in the
amygdala [13]. A simple model would predict that
downstream NMDA receptor-mediated CaMKII signal-
ing regulates CRF mRNA expression in the amygdala.
One major neuroendocrine system underlying an indi-
vidual’s capacity to cope with stress is the HPA axis
[14]. Besides the regulation of anxiety-like behavior,
CRF is a key coordinator of the HPA axis and an essen-
tial component in the mediation of behavioral responses
to stress [14]. In contrast to the increased CRF levels in
Figure 3 Abrogation of increased anxiety-related behavior of
GluN2B-YF mice by intraperitoneal injection of the CRF1
receptor antagonist NBI 27914. The reduced time spent in the
open arms shown by GluN2B-YF mice in the elevated plus-maze
test (WT, n = 10; YF, n = 12; F(1,37) = 7.12, p < 0.05, two-way
ANOVA/Tukey’s post-hoc test) was attenuated by intraperitoneal
injection of NBI 27914 (WT, n = 8; YF, n = 9; F(1,37) = 2.31, p > 0.1,
two-way ANOVA/Tukey’s post-hoc test). The asterisk indicates
significant differences. n.s., not significant.
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Figure 4 De-phosphorylation of Tyr-1472 and up-regulation of CRF expression after the EPM test and by NMDA-receptor stimulation.
(A) The level of Tyr-1472 phosphorylation in the amygdala of WT mice was decreased by the EPM test (control, n = 6; EPM test, n = 4; p < 0.05,
Student’s t-test). A representative blot is shown in the upper panel. (B) Real-time PCR analyses showed that CRF expression in the amygdala of
WT mice was increased after the EPM test (control, n = 6; EPM test, n = 4; p < 0.05, Student’s t-test). (C) Real-time PCR analyses showed that
NMDA stimulation (100 μM NMDA for 7 min) increased CRF expression in the amygdalae of WT mice (control, n = 6; NMDA stimulation, n = 6;
p < 0.05, Student’s t-test) but not in GluN2B-YF mice (control, n = 6; NMDA stimulation, n = 6; p > 0.2, Student’s t-test). (D) The same NMDA
stimulation also induced de-phosphorylation of Tyr-1472 in the amygdalae of WT mice (control, n = 5; NMDA stimulation, n = 5; p < 0.05,
Student’s t-test). A representative blot is shown in the upper panel. The asterisk indicates significant genotype differences. n.s., not significant.
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the amygdala (Figure 2A), we did not find any signifi-
cant differences in hypothalamic CRF levels between
GluN2B-YF mice and WT mice (Figure 2D). Consistent
with these findings, the basal levels of plasma ACTH in
GluN2B-YF mice were virtually unchanged compared to
those of WT mice (Figure 2F). Thus, the function of
Tyr-1472 phosphorylation may be different between
brain regions. Alternatively, in the hypothalamus, some
compensatory event might have occurred to mask the
hypothalamic phenotypes in GluN2B-YF mice.
There is widespread interest in CRF1 receptor antago-
nists for the treatment of anxiety disorders [21,27]: how-
ever, these potential therapies can influence the function
of the HPA axis in response to stress [28]. Tyr-1472
phosphorylation in GluN2B regulates anxiety-like beha-
vior through regulation of amygdaloid CRF expression
without altering the function of the HPA axis. There-
fore, blocking Tyr-1472 phosphorylation in the amyg-
dala may be a clinically effective means of treating
anxiety disorders without the potential risks associated
with blocking of the function of the HPA axis.
Conclusions
In summary, the present study demonstrates that the
cellular interaction between CRF signaling and NMDA
receptors, especially Tyr-1472 phosphorylation of
GluN2B, is necessary for the regulation of anxiety-like
behavior. GluN2B-YF mice should serve as a useful ani-
mal model to study the pathogenesis of anxiety disor-
ders and to develop therapeutic drugs for the disease.
Methods
Animals
Heterozygous GluN2B-YF mice [13] were successively
backcrossed to C57BL/6J mice to yield subsequent gen-
erations with a pure C57BL/6J genetic background. F10
heterozygous mice were crossed to each other to yield
homozygous mice and wild-type littermates. Male 8-12-
week old mice were used in this study. All experiments
and analyses were done in a completely blind manner.
Experiments with animals were carried out in accor-
dance with the guidelines for animal use issued by the
Committee of Animal Experiments, Institute of Medical
Science, University of Tokyo.
Elevated plus-maze (EPM) test
The elevated plus-maze test (EP-3002; O’ Hara & Co.,
Ltd., Tokyo, Japan) consisted of two open arms (25 × 5
cm) and two enclosed arms of the same size extending
from a central area (5 × 5 cm) and elevated 50 cm from
the ground. The ambient light level was 30 lux. The
mice were placed in the central square of the maze
facing one of the open arms. Mouse behavior was
recorded during a 10 min test period with a Macintosh
computer using Image EP 2.13× and Image EPC 2.03s×
(O’Hara & Co., Ltd.), a modified software based on the
public domain of NIH Image program. The following
conventional parameters were recorded: the number of
entries into open or closed arms and the time spent in
open or closed arms.
Real-time PCR
Mice were anesthetized with halothane and immediately
decapitated. Brains were then rapidly removed and frozen
by liquid nitrogen. Serial coronal sections (400 μm thick-
ness) were cryosectioned, and the various brain regions
were collected with a biopsy puncher. Total RNA was
isolated from the brain regions and reverse transcribed
with Superscript III (Invitrogen, Carlsbad, CA, USA).
Real-time PCR was performed with TaqMan primers on
an ABI PRISM 7900HT system (Applied Biosystems,
Foster City, CA, USA) according to the supplier’s proto-
col. The following intron-spanning primer sets were
used: HPRT (internal control), Mm0046968_m1;
CRF, Mm01293920_S1 (Applied Biosystems). Relative
expression levels were determined according to the
2-ΔΔCt method (Applied Biosystems, User Bulletin).
Measurements of CRF protein level
Serial coronal sections (200 μm) were cryosectioned,
and the amygdalae were collected [29]. CRF protein
levels were measured by using an enzyme-linked immu-
noassay kit (Mouse/Rat CRF-HS ELISA kit (YK131),
Yanaihara Institute Inc., Shizuoka, Japan) according to
the supplier’s protocol.
Measurements of plasma adrenocorticotropin-releasing
hormone (ACTH) levels
Mice were killed by rapid decapitation, and blood was
collected at around 9:00 AM. Serum was isolated and
frozen at -80°C until analysis. Basal plasma ACTH levels
were measured using an enzyme-linked immunoassay
(SRL Inc., Tokyo, Japan).
Intraperitoneal injection of CRF1 receptor antagonist
A non-peptide selective CRF1 receptor antagonist, NBI
27914 (dissolved at 10 mg/ml in DMSO, 10 mg/kg body
weight, Tocris, Bristol, UK) [30] or vehicle (DMSO) was
injected intraperitoneally 45 min before the EPM test.
Pharmacological treatment of brain slices
Coronal slices including the amygdala (400 μm thick-
ness) were prepared from 8- to 10-week-old mice and
placed in an interface-type holding chamber for at least
3 h. Slices were preincubated in ACSF [13] for 1 h and
then stimulated with 100 μM NMDA for 7 min.
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Preparation of lysate, immunoprecipitation and
immunoblotting
Preparation of lysate from the mouse brain and immu-
noblotting were performed as described previously [13].
For quantification, the immunoreacted protein bands
were analyzed with the NIH image software. The rabbit
polyclonal antibody against phospho-Tyr-1472/GluN2B
was described previously [31]. The mouse monoclonal
antibody against GluN2B was purchased from Millipore
(Billerica, MA, USA).
Statistical analysis
All data are expressed as the means ± SEM. Statistical
analysis was performed using Student’s t test, one-way
ANOVA, two-way ANOVA, and Tukey’s post hoc test.
Differences with p < 0.05 were considered as significant.
Abbreviations
ACTH: adrenocorticotropin-releasing hormone; ANOVA: analysis of variance;
CRF: corticotropin-releasing factor; EPM: elevated plus-maze; HPA:
hypothalamic-pituitary-adrenocortical; NMDA: N-methyl-D-aspartate.
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